Health BehaviorBENEFIT-CNCT06124131
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
A study testing Financial incentive for colorectal cancer screening, Financial incentive for flu shot and Financial incentive for COVID-19 shot in people with Health Behavior and Colorectal Cancer, run by Tulane University at 1 site in United States.
Trial summary
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. Read more about this study
- Who is it for?
- Ages 45 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Health Behavior, Colorectal Cancer, Influenza
- What is being tested?
- Financial incentive for colorectal cancer screening, Financial incentive for flu shot and Financial incentive for COVID-19 shot
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Nov 2023to 25 Mar 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 45 to 75
- Receive care at participating primary care clinic
- Due for colorectal cancer screening
- Ability to understand and speak English
Who cannot join
- Currently participating in another clinical trial or research study on colorectal cancer screening
- Unable or unwilling to give informed consent
Trial locations and contacts
1 site in 1 country.
United States1 site
Tulane University School of Medicine
New Orleans, Louisiana, 70112
About this study
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are:
- Do patient financial incentives for completing colorectal cancer screening increase screening completion?
- Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots?
Read more
Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment.
Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.
- Conditions
- Health Behavior, Colorectal Cancer, Influenza, COVID-19, Vaccine Hesitancy, Vaccine-Preventable Diseases
- Being tested
- Financial incentive for colorectal cancer screening, Financial incentive for flu shot, Financial incentive for COVID-19 shot
- Keywords
- Cancer screening, Preventive healthcare, Vaccine uptake, Patient financial incentives, Federally qualified health center, Health services
- Medical subject headings
- Health Behavior, Colorectal Neoplasms, Influenza, Human, COVID-19, Vaccination Hesitancy, Vaccine-Preventable Diseases, Patient Acceptance of Health Care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Financial incentive for colorectal cancer screeningBehavioural
$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
Financial incentive for flu shotBehavioural
$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
Financial incentive for COVID-19 shotBehavioural
$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
| Study group | Role | What they receive |
|---|---|---|
| Full financial incentives | Experimental | $50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening Receives: Behavioral: Financial incentive for colorectal cancer screening; Behavioral: Financial incentive for flu shot; Behavioral: Financial incentive for COVID-19 shot |
| Partial financial incentives | Active comparator | $50/service patient financial incentive for completion of: COVID-19 shot, flu shot Receives: Behavioral: Financial incentive for flu shot; Behavioral: Financial incentive for COVID-19 shot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in Percent of Participants Completing Colorectal Cancer Screening Between Study Arms
Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment
Measured: Two months
Secondary outcomes (4)
Difference in Percent of Participants Completing COVID-19 Shot Between Study Arms
Completion of COVID-19 shot as documented in electronic health record within two months of study enrollment
Measured: Two months
Difference in Percent of Participants Completing Flu Shot Between Study Arms
Completion of flu shot as documented in electronic health record within two months of study enrollment
Measured: Two months
Difference in Percent of Participants Completing at Least One of the Following Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot
Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *OR* flu shot as documented in electronic health record within two months of study enrollment
Measured: Two months
Difference in Percent of Participants Completing All Three Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot
Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *AND* flu shot as documented in electronic health record within two months of study enrollment
Measured: Two months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2023
- Study start11 Nov 2023
- Primary completion25 Mar 2024
- Study completion25 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Health BehaviorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to a study arm for the duration of their two months in the study
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tulane University
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Marie A Krousel-Wood, MD, MSPH, Principal investigator, Tulane University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06124131
- Sponsor's protocol ID
- 2020-1600-BENC
- Other IDs
- OT2HL158287
- Acronym
- BENEFIT-C
- Status last verified
- Apr 2025
- First submitted
- 3 Nov 2023
- Last updated
- 4 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No IPD will be shared with other researchers
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
- ClinicalTrials.gov ID
- NCT06124131
- Acronym / sponsor ID
- BENEFIT-C / 2020-1600-BENC
- Conditions
- Health Behavior, Colorectal Cancer, Influenza, COVID-19, Vaccine Hesitancy, Vaccine-Preventable Diseases
- Keywords
- Cancer screening, Preventive healthcare, Vaccine uptake, Patient financial incentives, Federally qualified health center, Health services
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Tulane UniversityUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 11 Nov 2023 (actual)
- Primary completion
- 25 Mar 2024 (actual)
- Study completion
- 25 Mar 2024 (actual)
- First posted
- 9 Nov 2023 (actual)
- Results
- Posted 4 May 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are:
- Do patient financial incentives for completing colorectal cancer screening increase screening completion?
- Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots?
Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment.
Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to a study arm for the duration of their two months in the study
| Arm | Type | Receives |
|---|---|---|
| Full financial incentives | Experimental | Behavioral: Financial incentive for colorectal cancer screening, Behavioral: Financial incentive for flu shot, Behavioral: Financial incentive for COVID-19 shot$50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening |
| Partial financial incentives | Active comparator | Behavioral: Financial incentive for flu shot, Behavioral: Financial incentive for COVID-19 shot$50/service patient financial incentive for completion of: COVID-19 shot, flu shot |
Who may qualify
- Ages
- 45 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 45 to 75
- Receive care at participating primary care clinic
- Due for colorectal cancer screening
- Ability to understand and speak English
Key exclusion criteria (2 listed)
- Currently participating in another clinical trial or research study on colorectal cancer screening
- Unable or unwilling to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Financial incentive for colorectal cancer screening$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment | Behavioural | Full financial incentives |
| Financial incentive for flu shot$50 incentive paid to participant for completion of flu shot within 2 months of enrollment | Behavioural | Full financial incentives, Partial financial incentives |
| Financial incentive for COVID-19 shot$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment | Behavioural | Full financial incentives, Partial financial incentives |
Primary outcome
Difference in Percent of Participants Completing Colorectal Cancer Screening Between Study Arms
Time frame: Two months
Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment
4 secondary outcomes
Difference in Percent of Participants Completing COVID-19 Shot Between Study Arms
Time frame: Two months
Difference in Percent of Participants Completing Flu Shot Between Study Arms
Time frame: Two months
Difference in Percent of Participants Completing at Least One of the Following Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot
Time frame: Two months
Difference in Percent of Participants Completing All Three Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot
Time frame: Two months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No. No IPD will be shared with other researchers
Related trials for Health Behavior
Not yet recruitingObservational study
Validation of the Healthcare Relationship Assessment Scale (ERA) in Health Sciences Students.
Health Adult Subjects, Communication
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marie A Krousel-Wood, MD, MSPH principal investigator
Tulane University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Financial incentive for colorectal cancer screening, Financial incentive for flu shot and Financial incentive for COVID-19 shot in people with Health Behavior and Colorectal Cancer, run by Tulane University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 May 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in Percent of Participants Completing Colorectal Cancer Screening Between Study Arms (time frame: Two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2025.